| abstract |
The present invention relates to a novel piperazine derivative, to a pharmaceutically acceptable salt or an optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition containing same as an active ingredient for preventing or treating metabolic disorders. The novel piperazine derivative and the pharmaceutically acceptable salt or the isomer thereof, according to the present invention, have excellent in vivo absorptivity and outstanding safety in the human body, since the present invention has a higher water solubility than those of compounds conventionally known as GPR119 activators and has low cytotoxicity. Moreover, since the present invention has the excellent effect of promoting cAMP by activating GPR119, thereby having the significantly outstanding effect of reducing blood glucose in a single dose, the present invention can be effectively used as a pharmaceutical composition for preventing or treating obesity, type I diabetes, type II diabetes, inadequate glucose tolerance, insulin tolerance, hyperglycemia, hyperlipemia, hypertriglyceridemia, hypercholesterolemia, dyslipidemia, or X syndrome which are treatable by activating GPR119. |